Home » News » Valeant to acquire Dow Pharmaceuticals

Valeant to acquire Dow Pharmaceuticals

Marc Barberby Marc Barber


US-based Valeant Pharmaceuticals International has agreed to acquire Dow Pharmaceutical Sciences, a privately held US dermatology company, for $285 million (£190 million)

Marc Barber

Marc Barber

Marc was editor of GrowthBusiness from 2006 to 2010. He specialised in writing about entrepreneurs, private equity and venture capital, mid-market M&A, small caps and high-growth businesses.

Related Stories

News

General Election 2024 – what do scale-ups want to see?

The General Election will be on July 4, 2024, with political parties scrambling to get their policies together. What do high-growth firms want?

News

ThinCats to back high-growth companies with £300m fund

The new fund is for high-growth and owner-managed businesses based in London, the South East, North West and the Midlands

News

Fastest-growing companies in the UK revealed

The eighth annual FT1000 rankings is based on revenue growth in the three years to 2022

News

Litestream Ventures unveils plans for ‘click-to-invest’ TV series  

The venture media firm is hoping the series will challenge the likes of Dragons’ Den

Related Topics

Pharmaceutical industry